Related Experiment Video

Updated: May 10, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme

R J Atkins1, S S Stylli, R B Luwor

  • 1Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia. ratkins@student.unimelb.edu.au

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|June 18, 2013
PubMed

Insights

Glioblastoma multiforme (GBM) is a deadly brain cancer with poor survival rates. This review explores glycogen synthase kinase 3 beta (GSK-3β) as a potential target for new glioblastoma treatments.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Glioblastoma multiforme (GBM) is an aggressive brain tumor with a dismal prognosis and limited treatment options.
  • Current therapies for gliomas are often ineffective due to inherent resistance to chemotherapy and radiotherapy, and their invasive nature.
  • There is a critical need for novel therapeutic strategies to improve outcomes for GBM patients.

Purpose of the Study:

  • To review the role of glycogen synthase kinase 3 beta (GSK-3β) in gliomagenesis.
  • To examine the activity and function of GSK-3β within various signaling pathways relevant to brain tumor development.

Main Methods:

  • Literature review of scientific articles and research studies.
  • Analysis of signaling pathways implicated in glioma development and survival.
  • Focus on the protein kinase GSK-3β and its molecular functions.

Main Results:

  • GSK-3β is implicated in the development and survival of malignant gliomas.
  • The review details GSK-3β's involvement in multiple signaling cascades.
  • Understanding GSK-3β's function is key to developing targeted therapies.

Conclusions:

  • GSK-3β represents a promising molecular target for novel glioblastoma therapies.
  • Targeting GSK-3β may overcome resistance to conventional treatments.
  • Further research into GSK-3β pathways could lead to improved glioblastoma treatment modalities.
Keywords:
CancerGSK-3βGlioblastoma multiformePI3-KWnt

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...